Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis
Nivolumab plus ipilimumab is unlikely to be cost-effective as first-line therapy for unresectable HCC from US health care payer perspective. However, extended dosing interval or price reductions may render the regimen economically viable, with important implications for clinical practice, payers, and policy.
Authors
- Zhengxiong Li (ORCID: https://orcid.org/0000-0003-1880-5096)
- Wensheng Liu (ORCID: https://orcid.org/0000-0003-4357-1893)
- Junbo Ge (ORCID: https://orcid.org/0000-0002-8318-4882)
- Jiefeng Luo
- Lu Han (ORCID: https://orcid.org/0000-0002-9198-6455)
- Qiong Du
- Sizhen Cai
- Chengxia Gui
- Xinyi Mo
Institutions
- Shanghai Medical College of Fudan University (CN)
- Sun Yat-sen University (CN)
- Xuzhou Medical College (CN)
- Fudan University Shanghai Cancer Center (CN)
- China Power Engineering Consulting Group (China) (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/cncr.70259
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00